Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes
Top Cited Papers
Open Access
- 1 January 2004
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (1) , 11-20
- https://doi.org/10.1056/nejmoa035144
Abstract
Nucleoside analogues against herpes simplex virus (HSV) have been shown to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent sexual transmission of HSV. We followed 1484 immunocompetent, heterosexual, monogamous couples: one with clinically symptomatic genital HSV-2 and one susceptible to HSV-2. The partners with HSV-2 infection were randomly assigned to receive either 500 mg of valacyclovir once daily or placebo for eight months. The susceptible partner was evaluated monthly for clinical signs and symptoms of genital herpes. Source partners were followed for recurrences of genital herpes; 89 were enrolled in a substudy of HSV-2 mucosal shedding. Both partners were counseled on safer sex and were offered condoms at each visit. The predefined primary end point was the reduction in transmission of symptomatic genital herpes. Clinically symptomatic HSV-2 infection developed in 4 of 743 susceptible partners who were given valacyclovir, as compared with 16 of 741 who were given placebo (hazard ratio, 0.25; 95 percent confidence interval, 0.08 to 0.75; P=0.008). Overall, acquisition of HSV-2 was observed in 14 of the susceptible partners who received valacyclovir (1.9 percent), as compared with 27 (3.6 percent) who received placebo (hazard ratio, 0.52; 95 percent confidence interval, 0.27 to 0.99; P=0.04). HSV DNA was detected in samples of genital secretions on 2.9 percent of the days among the HSV-2–infected (source) partners who received valacyclovir, as compared with 10.8 percent of the days among those who received placebo (P<0.001). The mean rates of recurrence were 0.11 per month and 0.40 per month, respectively (P<0.001). Once-daily suppressive therapy with valacyclovir significantly reduces the risk of transmission of genital herpes among heterosexual, HSV-2–discordant couples.Keywords
This publication has 31 references indexed in Scilit:
- Quantitative Stability of DNA after Extended Storage of Clinical Specimens as Determined by Real-Time PCRJournal of Clinical Microbiology, 2002
- Reactivation of Genital Herpes Simplex Virus Type 2 Infection in Asymptomatic Seropositive PersonsNew England Journal of Medicine, 2000
- A Prospective Study of New Infections with Herpes Simplex Virus Type 1 and Type 2New England Journal of Medicine, 1999
- Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.Journal of Clinical Investigation, 1997
- A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study GroupArchives of internal medicine (1960), 1996
- Virologic Characteristics of Subclinical and Symptomatic Genital Herpes InfectionsNew England Journal of Medicine, 1995
- Transmission of Genital Herpes in Couples with One Symptomatic and One Asymptomatic Partner: A Prospective StudyThe Journal of Infectious Diseases, 1988
- Acquisition of Genital Herpes from an Asymptomatic Sexual PartnerNew England Journal of Medicine, 1986
- Frequency of Acquisition of First-episode Genital Infection with Herpes Simplex Virus from Symptomatic and Asymptomatic Source ContactsSexually Transmitted Diseases, 1985
- A Double-Blind Study of Oral Acyclovir for Suppression of Recurrences of Genital Herpes Simplex Virus InfectionNew England Journal of Medicine, 1984